Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The anti-cancer drug Avastin is as effective in fighting macular degeneration as Lucentis, which, however is 40 times more expensive than the cancer fighting medicine, according to results of clinical trials published in the United States.
The study compares Avastin (bevacizumab) to Lucentis (ranibizumab), which both have been developed by US firm Genentech, owned by Swiss laboratory Roche.
During the trials, scientists randomly assigned 1,208 patients with neovascular macular degeneration - a condition that leads to the gradual loss of central vision - to receive injections in the eye of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation.
"At one year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule," reported the authors of the study, including Doctor Juan Grunwald from the University of Pennsylvania.
"Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly."
However, the costs of the treatments were vastly different.
The average cost in the ranibizumab group per patient was $23,400 compared to $385 per patient in the bevacizumab group, the researchers said.
The study appears in the latest issue of The New England Journal of Medicine.
js/mk/mm
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments